About the Joint Formulary
The Joint Formulary is co-ordinated by a small group of primary and secondary care representatives including GPs, consultants and pharmacists. The Milton Keynes Prescribing Advisory Group (MKPAG), in collaboration with relevant specialists, develops the chapters.
To support education, reduction of errors and stock control the formulary will not include all licensed products in a class. When choosing a drug for inclusion in the formulary, the agent with the widest range of therapeutic indications and best quality published evidence showing clinically beneficial outcomes will be chosen. In most cases a maximum of 2-3 drugs of the same class will be sufficient to cover 80-90% of prescribing.
New Drugs
Generally, new drugs will not be added to the formulary within one year of their launch, unless they are considered to be a radical advance in disease management above anything else available, and that the safety profile stands rigorous examination (there are too many examples of drugs withdrawn within a short period of launching).
Keeping up to date
Each chapter, with the exception of Chapter 5 Infections, is scheduled for review every two years, but reviews may be more frequent if compelling NEW evidence becomes available. The review process follows a similar pattern of wide consultation as the initial chapter production.
Changes to a chapter may occasionally become necessary between reviews, for example, when the Milton Keynes Prescribing Advisory Group (MKPAG) approve new therapies, or a drug is withdrawn from supply. These changes will be made within 3 months of the MKPAG agreement on the web-based version of the formulary.
If you would like help implementing the Joint Formulary...
Please contact: Formulary Services Manager (for both Primary and Secondary care)
Dupe Fagbenro
Principal Pharmacist, MKUH & MKCCG
Email address: dupe.fagbenro@nhs.net
Last updated by: Dupe Fagbenro on 27-04-2018 13:26
-
BNF
-
NICE
-
Summary of product characteristics
